All News

My choice to not undergo chemotherapy for breast cancer was not an easy one, but looking back, I don’t regret it.

The FDA has set a date to decide whether or not to approve momelotinib for myelofibrosis, a rare type of blood cancer.

Like all good oncology nurse practitioners, she has a deep knowledge of cancer medicine, and I would trust her to care for anyone in my family.

If approved, the Lynparza-based regimen would become the first combination of a PARP inhibitor and a hormonal agent for metastatic castration-resistant prostate cancer.

A patient with metastatic breast cancer recalls the emotional experience of being among the thousands of attendees who gave a standing ovation in an auditorium in Chicago when the results of the phase 3 DESTINY-Breast04 trial — which recently led to the FDA approval of Enhertu in HER2-low disease — were presented at the 2022 ASCO Annual Meeting.

Cancer and COVID-19 took away my yearly “benchmarks” of time, when I fly out to see friends and family.

Prior to my breast cancer diagnosis, my only goal in life was for my son to turn 16 so he could drive me to and from the local bars. Now I can’t help but think that my cancer was meant for me to change my life.

Janet brings our values at Fox Chase Cancer Center to life.

As I recover from the traumatic effects of cancer, I’m realizing that success has much to do with mindset and optimism.

I was shocked at a recent doctor appointment when practically nobody in the office was wearing a mask.

A new study will analyze the effect of exercise on chemotherapy tolerability and outcomes in patients with colon cancer.

The researchers hypothesize that treatment with the investigational drug combined with chemoradiotherapy may reduce the need for invasive surgery to remove the rectum and surrounding tissue in this patient population.

A phase 2 trial will analyze the novel drug ART4215 with Talzenna, a PARP inhibitor, for patients with BRCA-deficient breast cancer.

I’m playing the cancer cards dealt to me as best I can, and am trying to stay healthy.

A psychiatrist advises patients with cancer to speak up about their mental health concerns during cancer treatment, as there are tools that can guide best next steps.

After my dad died of colorectal cancer, I knew I had to continue advocacy work in his honor.

Janice is an exemplary nurse at Fox Chase Cancer Center and has been a member of various teams across the institution for more than 30 years.

Val always goes above and beyond, and she holds herself to an impeccably high standard.

After findings from an early-phase trial showed that the novel drug was associated with anti-tumor activity, investigators decided to continue enrolling more patients with ER-positive, HER2-negative metastatic breast cancer.

The way I saw it was that I could either die from cancer, or from the side effects from the clinical trial. It was a difficult decision to make, but I am glad I chose it.

Gender be damned, a mother bear’s “fierce compassion” became my default mode as I cared for my ailing adventure partner and soul mate.

From “EastEnders” star Samantha Womack announcing her breast cancer diagnosis in a tribute to Olivia Newton-John to a famous fashion designer’s death from liver cancer, here’s what’s happening in the oncology space this week.

A stage 3 colorectal cancer survivor shares her story of being diagnosed right before the COVID-19 pandemic.

The FDA’s approval of Enhertu marks the first approval of a drug for patients with HER2-mutant unresectable or metastatic non-small cell lung cancer.

The use of five or more medicines — as well as some drugs that could be deemed inappropriate — may put older patients with cancer at a higher risk for complications, such as weakness.

The FDA approved Tabrecta for patients with non-small cell lung cancer who have a mutation that led to MET exon 14 skipping.

“Love Story,” the story about a young woman who falls in love and then dies of cancer, affects me differently now than it did when I was a teenager and no experience with either love or cancer.

The FDA’s decision to grant the investigational drug elacestrant a priority review for patients with ER-positive, HER2-negative advanced or metastatic breast cancer was based on data that showed the treatment bested standard-of-care in terms of improving survival.